Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
Total Revenues of $15.4 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe
Record Revenues of $16.5 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious
Results Demonstrate an Increased Survival Rate for Patients Treated with Epicel CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of
CAMBRIDGE, Mass. , March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI ® (autologous cultured chondrocytes on porcine collagen
Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second
Total Net Revenues of $32.3 Million and Net Income of $3.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported
58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results
Product Revenues of $30.5 Million Increase 36% Over Third Quarter 2018 Full Year 2019 Revenue Guidance Raised to $116 to $118 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
Record Second Quarter Product Revenues of $26.2 Million Represent a 38% Increase Over Second Quarter 2018 Full Year 2019 Revenue Guidance Raised to $112 to $116 Million Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation
Product Revenues of $20.0 Million Reported for the Second Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported
